Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mink Therapeutics Inc
(NQ:
INKT
)
0.8200
+0.0123 (+1.52%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mink Therapeutics Inc
< Previous
1
2
Next >
MiNK Reports Second Quarter 2024 Results and Business Update
August 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
August 01, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
July 31, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 05, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
May 22, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Reports First Quarter 2024 Results
May 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
May 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
April 30, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
April 08, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Reports Fourth Quarter and Year-End 2023 Results
March 21, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
March 07, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
March 06, 2024
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
From
MiNK Therapeutics
Via
GlobeNewswire
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
February 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
February 06, 2024
Treatment with agenT-797 Showed Improved Survival in Severe Respiratory Distress
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
January 30, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
December 20, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2023 Results
November 09, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
November 03, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
October 30, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
September 27, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Participate in September Investor Conferences
August 24, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Second Quarter 2023 Results
August 10, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
July 28, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 05, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
May 22, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
May 18, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
May 11, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
April 27, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
April 18, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
March 30, 2023
From
Agenus Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.